39,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
20 °P sammeln
  • Broschiertes Buch

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) drugs are widely used therapeutics for the treatment of pain and inflammation. They showed great promise due to their synthetic viability and affordability. Traditional NSAIDs, such as Aspirin, Naproxen, Piroxicam, Ibuprofen, Diclofenac, etc., inhibit both COX-1 and COX-2, which accounts for NSAIDs anti-inflammatory effects as well as their notorious side effects of GI toxicity and blood thinning. Thus, inhibition of COX-2 over COX-1 should be useful for treatment of inflammation without incurring the side effects associated with inhibition of…mehr

Produktbeschreibung
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) drugs are widely used therapeutics for the treatment of pain and inflammation. They showed great promise due to their synthetic viability and affordability. Traditional NSAIDs, such as Aspirin, Naproxen, Piroxicam, Ibuprofen, Diclofenac, etc., inhibit both COX-1 and COX-2, which accounts for NSAIDs anti-inflammatory effects as well as their notorious side effects of GI toxicity and blood thinning. Thus, inhibition of COX-2 over COX-1 should be useful for treatment of inflammation without incurring the side effects associated with inhibition of COX-1. Acyl hydrazones has occupied a prominent class that are having versatile chemical reactivity precursors and intermediates of various essential organic molecules such as polymers, pharmaceuticals and heterocycles. This book describes the history, previous literature information, molecular modelling studies and biological screening of N-Acyl hydrazones as potential Anti-Inflammatory activity.
Autorenporträt
Prof.Rambabu Gundla is currently in GITAM deemed to be University Hyderabad. He worked as a Principal Scientist in Collaborative drug discovery research, GVK BIO, Hyderabad. Fifteen years of experience in Rational Drug Design and Medicinal Chemistry. Worked for industry almost 10 years and executed number drug discovery projects.